• 中国科技论文统计源期刊
  • 中国科技核心期刊
  • 美国CA、俄罗斯AJ收录
高级检索

糖皮质激素联合小剂量利妥昔单抗治疗初治和复发原发免疫性血小板减少症的疗效观察

罗璐遥, 吴娅琦, 李小良, 李护君, 张琦, 闫志凌, 张焕新, 徐开林, 李振宇

罗璐遥, 吴娅琦, 李小良, 李护君, 张琦, 闫志凌, 张焕新, 徐开林, 李振宇. 糖皮质激素联合小剂量利妥昔单抗治疗初治和复发原发免疫性血小板减少症的疗效观察[J]. 徐州医科大学学报, 2020, 40(5): 347-350. DOI: 10.3969/j.issn.2096-3882.2020.05.008
引用本文: 罗璐遥, 吴娅琦, 李小良, 李护君, 张琦, 闫志凌, 张焕新, 徐开林, 李振宇. 糖皮质激素联合小剂量利妥昔单抗治疗初治和复发原发免疫性血小板减少症的疗效观察[J]. 徐州医科大学学报, 2020, 40(5): 347-350. DOI: 10.3969/j.issn.2096-3882.2020.05.008
shu
LUO Luyao, WU Yaqi, LI Xiaoliang, LI Hujun, ZHANG Qi, YAN Zhiling, ZHANG Huanxin, XU Kailin, LI Zhenyu. Observation of curative effect of glucocorticoid combined with low-dose rituximab in primary and recurrent primary immune thrombocytopenia[J]. Journal of Xuzhou Medical University, 2020, 40(5): 347-350. DOI: 10.3969/j.issn.2096-3882.2020.05.008
Citation: LUO Luyao, WU Yaqi, LI Xiaoliang, LI Hujun, ZHANG Qi, YAN Zhiling, ZHANG Huanxin, XU Kailin, LI Zhenyu. Observation of curative effect of glucocorticoid combined with low-dose rituximab in primary and recurrent primary immune thrombocytopenia[J]. Journal of Xuzhou Medical University, 2020, 40(5): 347-350. DOI: 10.3969/j.issn.2096-3882.2020.05.008
shu

糖皮质激素联合小剂量利妥昔单抗治疗初治和复发原发免疫性血小板减少症的疗效观察

  • 徐州医科大学附属医院血液科, 江苏 徐州 221002

基金项目: 

国家自然科学基金(81770223,81570183)

江苏省医学重点人才(ZDRCA2016052)

详细信息
    通讯作者:

    李振宇,E-mail:Lizhenyumd@163.com

  • 中图分类号: R558+.2

Observation of curative effect of glucocorticoid combined with low-dose rituximab in primary and recurrent primary immune thrombocytopenia

  • Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China

摘要

    摘要
  • 摘要: 目的 比较糖皮质激素联合小剂量利妥昔单抗治疗初治和复发原发免疫性血小板减少症(ITP)的疗效。方法 51例患者纳入研究,男17例,女34例,中位年龄27(18~69)岁;初治ITP 28例(初治组),常规糖皮质激素治疗后复发ITP 23例(复发组),其中糖皮质激素依赖20例,糖皮质激素无效3例。治疗方案均为:第1~4天大剂量地塞米松40 mg/d口服,第5~7天泼尼松60 mg/d口服,第8~14天泼尼松30 mg/d口服,第15~21天泼尼松20 mg/d口服,第22~28天泼尼松10 mg/d口服;第7、14、21、28天小剂量利妥昔单抗100 mg静脉输注。观察比较初治组和复发组ITP患者的疗效及安全性。结果 治疗第4天,2组血小板计数均较治疗前升高,差异有统计学意义(P<0.05),组间差异无统计学意义(P>0.05);治疗第7天,2组血小板计数继续升高,组间差异无统计学意义(P>0.05);治疗第14、28天,2组血小板计数均处于相对安全水平,组间差异无统计学意义(P>0.05)。治疗第28天和第6个月,初治组患者总有效率均高于复发组,但差异无统计学意义(P>0.05)。2组不良反应发生率的差异无统计学意义(P>0.05)。结论 糖皮质激素联合小剂量利妥昔单抗治疗初治和复发原发免疫性血小板减少症的疗效相当,无严重不良反应发生。
    Abstract: Objective To compare the efficacy of glucocorticoid combined with low-dose rituximab in the treatment of primary and recurrent primary immune thrombocytopenia (ITP). Methods A total of 51 patients were included in the study, 17 males and 34 females, with a median age of 27 (18-69) years; 28 patients with initial ITP (initial treatment group), 23 patients with recurrent ITP (recurrence group) after routine glucocorticoid treatment, including 20 patients with glucocorticoid dependence and 3 patients with ineffective glucocorticoid. The treatment regimen was: large dose of dexamethasone 40 mg/d on days 1-4, prednisone 60 mg/d on days 5-7, prednisone 30 mg/d on days 8-14, prednisone 20 mg/d on day 15-21, prednisone 10 mg/d on days 22-28, low dose of rituximab 100 mg intravenous drip on days 7, 14, 21 and 28. The efficacy and safety of ITP patients in initial treatment group and recurrence group were observed and compared. Results On the fourth day of treatment, the platelet count of the two groups was higher than that before treatment, the difference was statistically significant (P<0.05), there was no statistically significant difference between the two groups (P>0.05). On the seventh day of treatment, the platelet count of the two groups continued to rise, without statistically significant difference between the two groups (P>0.05). On the fourteenth and 28th days of treatment, the platelet count of the two groups were in a relatively safe level, without statistically significant difference between the two groups (P>0.05). On the 28th day and the 6th month of treatment, the total effective rate in the initial treatment group was higher than that in the recurrence group, but the difference was not statistically significant (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions Glucocorticoid combined with low-dose rituximab has similar efficacy in the treatment of primary and recurrent immune thrombocytopenia, and there is no serious adverse reactions.
    • HTML全文
    • 参考文献(13)
  • [1]

    Wei Y,Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood, 2016, 127(3): 296-302; quiz 370. DOI: 10.1182/blood-2015-07-659656.
    [2]

    Perosa F, Prete M, Racanelli V. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic[J]. J Intern Med, 2010, 267(3): 260-277. DOI: 10.1111/j.1365-2796.2009.02207.x.
    [3]

    Zaja F, Battista ML, Pirrotta MT, et al. Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura[J]. Haematologica, 2008, 93(6): 930-933. DOI: 10.3324/haematol.12206.
    [4]

    Wang J, Li Y, Wang C, et al. Efficacy and safety of the combination treatment of rituximab and dexamethasone for adults with primary Immune thrombocytopenia (ITP): a meta-analysis[J/OL]. Biomed Res Int, 2018, 2018: 1316096. DOI: 10.1155/2018/1316096.
    [5]

    Arnold DM,Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura[J]. Ann Intern Med, 2007, 146(1): 25-33.
    [6] 邢伟伟, 李振宇, 闫志凌, 等. 两种糖皮质激素联合小剂量利妥昔单抗方案治疗成人原发免疫性血小板减少症的疗效比较[J]. 中华血液学杂志, 2013, 34(5): 409-412. DOI: 10.3760/cma.j.issn.0253-2727.2013.05.007.
    [7] 中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(2): 89-93. DOI: 10.3760/cma.j.issn.0253-2727.2016.02.001.
    [8]

    Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis[J/OL]. Lancet Haematol, 2016, 3(10): e489-e496. DOI: 10.1016/S2352-3026(16)30109-0.
    [9]

    Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial[J]. Lancet, 2015, 385(9978): 1653-1661. DOI: 10.1016/S0140-6736(14)61495-1.
    [10]

    Mazzucconi MG, Fazi P, Bernasconi S, et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience[J]. Blood, 2007, 109(4): 1401-1407. DOI: 10.1182/blood-2005-12-015222.
    [11]

    Borst F, Keuning JJ, van Hulsteijn H, et al. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults[J]. Annals of hematology, 2004, 83(12): 764-768. DOI: 10.1007/s00277-004-0908-1.
    [12] 闫志凌, 李振宇, 张焕新, 等. 大剂量地塞米松联合小剂量利妥昔单抗作为二线方案治疗65例原发免疫性血小板减少症患者的临床观察[J]. 中华血液学杂志, 2015, 36(3): 206-209. DOI: 10.3760/cma.j.issn.0253-2727.2015.03.007.
    [13] 刘俊秀, 张焕新, 李德鹏, 等. 利妥昔单克隆抗体治疗不同激素敏感性的ITP患者的疗效比较[J]. 中国实验血液学杂志, 2019, 27(5): 1602-1606. DOI: 10.19746/j.cnki.issn1009-2137.2019.05.037.
    • 相关文章
    • 施引文献(5)

  • 期刊类型引用(5)

    1. 刘彬，孙雯娟，杜小莉. 利妥昔单抗在中国超说明书用药的临床研究进展. 临床药物治疗杂志. 2024(09): 24-29 . 百度学术
    2. 梁秋，黄忠光，朱妮娜. 糖皮质激素联合小剂量利妥昔单抗注射液治疗难治性原发性免疫性血小板减少症的效果及不良反应发生率. 吉林医学. 2024(12): 3075-3078 . 百度学术
    3. 方华，何璐伟，汪运鹏，张蕾，李红. 艾曲泊帕联合重组人血小板生成素在免疫性血小板减少症患儿中的应用. 中国合理用药探索. 2023(12): 44-48 . 百度学术
    4. 吴东升，王前，袁梅，陈小欢. 糖皮质激素联合重组人白介素-11治疗成人重症原发免疫性血小板减少症的近期疗效及安全性. 临床合理用药杂志. 2022(06): 118-120 . 百度学术
    5. 杨青，宋元华，吕瑜，宋春艳，张翼宇. 免疫抑制剂治疗儿童慢性免疫性血小板减少症的临床研究. 中国医刊. 2021(02): 209-212 . 百度学术

    其他类型引用(0)

    • 资源附件(0)
计量
  • 文章访问数:  827
  • HTML全文浏览量:  1
  • PDF下载量:  834
  • 被引次数: 5
出版历程
  • 收稿日期:  2020-03-09
  • 修回日期:  2020-05-09

目录

摘要
HTML全文
    参考文献(13)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    网站版权 © 《徐州医科大学学报》编辑部 苏ICP备10010028号

    电子邮件：xzhmuxb@xzhmu.edu.cn

    地址：徐州市淮海西路84号

    电话：15380140709（1.13-2.20寒假期间请拨打手机）　0516-85748483

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计